Policy changes Backwork has recorded, newest first. The most recent change on record is from October 24, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
86,510 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Genetic Test: Alzheimer's Disease | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Genetic Test: Alpha-1 Antitrypsin Deficiency | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Genetic Test: Alpha and Beta Thalassemia | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Genetic Test: Allopurinol Sensitivity (HLA-B*5801) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Genetic Test: Testing for the Diagnosis and Management of Mental Health Conditions | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Genetic Test: X-Linked Opitz G/BBB Syndrome, MID1 Mutation Testing | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Genetic Test: Next-Generation Sequencing for Cancer Susceptibility Panels | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Genetic Test: Molecular Markers in Fine Needle Aspirates of the Thyroid | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Genetic Test: Analysis of MGMT Promoter Methylation in Malignant Gliomas | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Genetic Test: Germline Genetic Testing for Pancreatic Cancer Susceptibility Genes | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Genetic Test: Genetic (TPMT, NUDT15, CEP72) and Metabolite (6-MMP, 6-TGN) Testing for Thiopurine Treatment | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Gene Therapies for Hemophilia (Etranacogene dezaparvovec-drlb [e.g., Hemgenix]) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Gender Affirming Surgery | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Gemtuzumab Ozogamicin (e.g., Mylotarg) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Gemcitabine branded intravenous infusion (e.g., Avgemsi) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Gastroesophageal Reflux Disease (GERD), Magnetic Esophageal Ring | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Gastric Neurostimulation for Treatment of Gastric and/or Small Bowel Paresis | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Gastric Neurostimulation for Morbid Obesity | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Galectin Measurement | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Gait Analysis | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Functional Intracellular Analysis | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Foscarbidopa with foslevodopa (e.g., Vyalev) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Food and Chemical Sensitivity Testing | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Focal Treatments for Prostate Cancer | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Femoroacetabular Impingement, Surgical Treatment of | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Fecal microbiota, live-jslm (e.g., Rebyota) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Fecal Microbiota Transplantation for the Treatment of Clostridioides Difficile | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Fam-trastuzumab deruxtecan-nxki (e.g., Enhertu) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Factor XIII (e.g., Corifact, Tretten) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Factor X (e.g., Coagadex) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Factor VIII (e.g., Advate, Adynovate, Afstyla, Alphanate, Altuviiio, Eloctate, Esperoct, Jivi, Hemofil-M, Humate-P, Koate, Kovaltry, Novoeight, Nuwiq, Obizur, Recombinate, Wilate, Xyntha) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Factor IX (e.g., AlphaNine, Alprolix, BeneFIX, Idelvion, Ixinity, Mononine, Profilnine, Rebinyn, Rixubis) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Facet Joint Denervation | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Extracorporeal Membrane Oxygenation for Adult Conditions | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | External Enhanced Cardiac Counterpulsation (EECP) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Exagamglogene autotemcel (e.g., Casgevy) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Evinacumab-dgnb (e.g., Evkeeza) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Etelcalcetide (e.g., Parsabiv) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Extracorporeal Shock Wave Therapy for Plantar Fasciitis and Other Musculoskeletal Conditions | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Eribulin mesylate (e.g., HALAVEN) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Eptinezumab-jjmr (e.g., Vyepti) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Epiduroscopy | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Epidural Steroid Injections for Chronic Neck and Back Pain | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Epcoritamab-bysp (e.g., Epkinly) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Enzyme Replacement Therapy (ERT) for Fabry Disease: Agalsidase Beta (e.g., Fabrazyme) and Pegunigalsidase alfa (e.g., Elfabrio) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Enfortumab Vedotin-ejfv (e.g., Padcev) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Endovascular Stent Grafts for Disorders for the Thoracic Aorta | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Endovascular Procedures for Intracranial Arterial Disease and Extracranial Vertebral Artery Disease | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Endothelial Keratoplasty | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Emapalumab-LZSG (e.g., Gamifant) | New policy |